LCT 0.01
Funding Update: LCT Advancing NTCELL With Investor Backing
Living Cell Technologies (ASX:LCT) continues to advance its third clinical trial of NTCELL in Parkinson’s disease, with the backing of investors crucial to its potentially groundbreaking research.
Investor Presentation
LCT Executive Chairman, Professor Bernie Tuch and Chief Operating Officer, Dr Belinda Di Bartolo provide an update to investors on the company's latest activities and milestones, including the third clinical trial of NTCELL in Parkinson's disease.
Investor Webinar
Living Cell Technologies (ASX:LCT) invites investors to attend a webinar to be held from 11am AEDT (1pm New Zealand time) on Thursday, 10 March 2022. Register to attend via this link: https://attendee.gotowebinar.c...
LCT Interim CEO's term extended as NTCELL advances
LCT Executive Chairman, Professor Bernie Tuch’s appointment as Interim CEO extended, as company continues to advance NTCELL and other project opportunities to add value for shareholders.
Change of Address
The registered office address and principal place of business address for LCT has changed to Level 16, Tower 2, Darling Park, 201 Sussex Street, Sydney, NSW, 2000.